6 / 20
Page 26
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Biography
AntónioManuel da Silva RibeiroMota has completed hisMSc in
Medicine fromNova Medical School and finished his Residency
in Radiation Oncology from Instituto Português de Oncologia de
Lisboa Francisco Gentil in 2015 with the grade of 19.5/20.0 He
has undergone a professional training at Mount Vernon Cancer
in London in 2014, to improve his knowledge in Radiation Oncol-
ogy. He has completed his Clinical Scholars Research Training
(CSRT) from Harvard Medical School in 2018. Currently, he is
associated with Nova Medical School for the Oncology studies
and Volunteer Assistant with students from the 5
th
year of MSc
studies. He has published two papers in journals and presented
several oral communications in congress and symposium. His
area of interest includes Central Nervous System, Hematology
and Head and Neck cancer.
amsrmota@gmail.comAnalysing the impact of size of brain metastases in the
overall survival of patients with primary head and neck
cancer, melanoma and sarcoma
Antonio Manuel da Silva Ribeiro Mota
1, 2
, RoldaoM
1,2
, Silva P
1
,
Pedro C
1
, Ferreira N
1
, Fonseca J
1
, Viveiros C
1
, Fonseca
L
1
, Colaco R
1
, Matos A
1
, Netto E
1,2
and Santos F
1
1
Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPOLFG), Portugal
2
Nova Medical School, Portugal
Antonio Manuel da Silva Ribeiro Mota et al., J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-002
Introduction:
Management of brain metastases (BMs) depends on important
prognostic factors such as age, performance status (PS), primary cancer and the
status of extracranial disease. Until now, the size of brain metastasis (BM) is used
to decide the therapeutic approach but not as a prognostic factor.
Methods:
A retrospective and single center study of patients having primary head
and neck cancer, melanoma or sarcoma who were diagnosed of BMs from2006 to
2015 was analysed. Patients were selected by number of BMs (≥4) and/or by size
of the biggest BM (≥3cm). The primary outcome was to evaluate the association
between the size of BM and overall survival (OS) in months, and the second
outcome was to evaluate the association between whole brain radiotherapy
(WBRT) and OS in months. We compared the association by baselines covariates
using log-rank test and Cox proportional hazards regression.
Results:
66patientswerecollected(medianage63yearsold)withprimaryheadand
neck cancer, melanoma or sarcoma. In univariate analysis, there was no difference
in OS between gender, number of BMs and primary cancer. However, there was a
statistical difference in OS when the diameter of the biggest metastasis is ≥3cm
(difference in median OS=1.3 months, p<0.05). There was also an increase in OS
among patients treated withWBRT (difference inmedian OS=2.5months, p<0.05).
In a multivariate analysis, there was no difference in association between the size
of BM and OS (Hazard Ratio (HR) = 1.6, 95% CI: 0.82-3.2), p=0.16)
Conclusion:
This retrospective study shows no association between BMs’ size
and OS in patients with primary head and neck cancer, melanoma or sarcoma.
However, in this cohort, WBRT improves OS in the group of patients with ≥4 BMs
and/or one BM≥3cm.